華潤醫藥(03320.HK)旗下C1酯(酉每)抑制劑獲內地批藥物臨床試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

華潤醫藥(03320.HK)旗下C1酯(酉每)抑制劑獲內地批藥物臨床試驗

阿思達克 07-10 16:18

華潤醫藥(03320.HK)旗下華潤博雅生物C1酯(酉每)抑制劑(C1-INH)近日收到國家藥監局核准簽發的《藥物臨床試驗批准通知書》。 C1酯(酉每)抑制劑(C1-INH)用於治療成人和青少年急性腹部或面部遺傳性血管性水腫(HAE)急性發作。據悉該產品目前尚無國內企業生產銷售。(ca/w) ~

華潤醫藥(03320.HK)

Relevant Stocks

華潤醫藥(03320.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

華潤醫藥(03320.HK)旗下C1酯(酉每)抑制劑獲內地批藥物臨床試驗

Services

About Us

Agreement Statement